Dinaciclib

Phase 2Small molecule

Merck & Co.

Dinaciclib is one of 42 small molecule programs targeting Acral Lentiginous Melanoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acral Lentiginous MelanomaActive, not recruiting

Advanced Malignant Solid NeoplasmActive, not recruiting

Acral Lentiginous MelanomaPhase 2

Active, not recruiting

Advanced Malignant Solid NeoplasmPhase 1

Active, not recruiting

Competition

Competitive Landscape

43 competitors in Advanced Malignant Solid Neoplasm

#DrugCompanyPhaseTrials

Zyprexa

MMODAG GmbH

Phase 3

2 2

Lynparza

AstraZeneca

Phase 2

4 3

Ibrance

Pfizer

Phase 2

4 4

Mektovi

Pfizer

Phase 2

2 5

Taxol

Teva

Phase 2

2 6

Koselugo

AstraZeneca

Phase 2

2 7

Balversa

Johnson & Johnson

Phase 2

1 8

Retevmo

Eli Lilly

Phase 2

1 9

Keytruda

Merck & Co.

Phase 2

1 10

Talzenna

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Acral Lentiginous Melanoma

NCT00937937

Q3 2027

Phase 1Active, not recruiting

Advanced Malignant Solid Neoplasm

NCT01434316

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukemia3 trials

A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01650727·5 enrolled

A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01580228·44 enrolled

Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01515176·36 enrolled

Multiple Myeloma2 trials

Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01096342·16 enrolled

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01711528·41 enrolled

Acute Myeloid Leukemia1 trial

A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Terminated· AbbVie logo

AbbVie·Phase 1·NCT03484520·48 enrolled

Triple-Negative Breast Cancer1 trial

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01624441·40 enrolled

Breast Cancer1 trial

Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer

Completed·JJo Chien·Phase 1·NCT01676753·32 enrolled

5 more indications

Hematologic Malignancies1 trial

Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT02684617·75 enrolled

Melanoma1 trial

Dinaciclib in Treating Patients With Stage III-IV Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT01026324·12 enrolled

Pancreatic Cancer1 trial

Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01783171·42 enrolled

Acral Lentiginous Melanoma1 trial

A Phase II Trial of SCH 727965 (NSC 747135) in Patients With Stage IV Melanoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT00937937·72 enrolled

Advanced Malignant Solid Neoplasm1 trial

Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT01434316·121 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Dinaciclib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dinaciclib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dinaciclib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

Dinaciclib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Trials by Indication[1]

Chronic Lymphocytic Leukemia3 trials

Multiple Myeloma2 trials

Acute Myeloid Leukemia1 trial

Triple-Negative Breast Cancer1 trial

Breast Cancer1 trial

Hematologic Malignancies1 trial

Melanoma1 trial

Pancreatic Cancer1 trial

Acral Lentiginous Melanoma1 trial

Advanced Malignant Solid Neoplasm1 trial

References

Drug Info

Quick Facts

Related News